 In a tremendous overreaction, Cardiff lost 41 of its value over the discontinuation of a prostate cancer trial on September 13, 2022,. Combined ESMO 2022 oncology conference reportings by Amgen, Mirati Therapeutics and Cardiff show Onvansertib is best-in-class in metastatic colorectal cancer, the lead indication. 